Abeclib-150mg, powered by Abemaciclib, is a cutting-edge medication designed to treat advanced Treatment for Breast Cancer. This powerful drug, part of the CDK4/6 inhibitor class, works by targeting and blocking certain proteins in cancer cells, stopping their growth and division. It is specifically approved for hormone receptor-positive (HR+) and HER2-negative advanced breast cancer, either as a standalone treatment or combined…
Afanix 40 Mg, containing the active ingredient Afatinib, is a powerful medication used in the treatment of non-small cell lung cancer (NSCLC). It belongs to the group of medications known as tyrosine kinase inhibitors (TKIs) that target and block specific proteins responsible for cancer cell growth. This makes Afanix 40 Mg an essential treatment option for patients with Medication Of…
Hernix 40 mg, containing the active ingredientNeratinib, is a groundbreaking oral medication specifically designed for patients withearly-stage Targeted therapy for her2-positive breast cancer. It reduces the risk of cancer recurrence after initial treatments such as surgery or chemotherapy. As a tyrosine kinase inhibitor (TKI), Hernix targets and blocks specific proteins involved in cancer cell growth, helping prevent the spread and…
Hertinib-40mg (Neratinib) is an advanced oral medication specifically designed to treat early-stage HER2-positive breast cancer in patients who have completed prior trastuzumab-based therapy. As a targeted therapy, Hertinib-40mg works by inhibiting the HER2 protein, which is responsible for the growth and spread of cancer cells. By blocking this protein, Hertinib-40mg helps prevent cancer from returning, offering patients improved outcomes and…
Olanib 50mg & 150mg (Olaparib) is a leading-edge oral medication used to treat various cancers, specifically ovarian, breast, prostate, and pancreatic cancers. This powerful drug belongs to a class of treatments known as PARP Inhibitor For Prostate Cancer (Poly ADP-Ribose Polymerase inhibitors). It is designed to stop cancer cells from repairing themselves, slowing tumour growth and enhancing survival rates.
Palbocent 125 mg (Palbociclib) is an innovative oral medication used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Palbociclib, the active ingredient in Palbocent, is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6, enzymes that play a crucial role in the growth and division of cancer cells. By blocking…
Palbonix (Palbociclib) is a targeted therapy that has revolutionized the treatment of new breast cancer treatment. Available in 125mg and 100mg doses, Palbonix helps manage hormone receptor-positive and HER2-negative metastatic new breast cancer treatment. It works by inhibiting cyclin-dependent kinases 4 and 6 (CDK 4/6), crucial proteins involved in cell division, slowing down the growth of cancer cells.
Palboxen 125mg, containing the active ingredient Palbociclib, is a groundbreaking medication specifically designed for the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. As a cyclin-dependent kinase (CDK) 4/6 inhibitor, Palboxen 125mg is vital in slowing down the growth and spread of cancer cells, offering hope to patients whose cancer has progressed after previous treatments. When used…
Tucaxen 150mg, with the active ingredient Tucatinib, is a cutting-edge oral medication used in Her2 positive breast cancer treatment. Designed to target and inhibit the growth of cancer cells that overexpress the HER2 protein, Tucaxen 150mg is a key player in modern cancer therapy. It is often prescribed in combination with other cancer treatments, such as trastuzumab and capecitabine, to…
